Reconsidering pharmacotherapy for opioid use disorders

Opioids relieve pain but are dangerous and highly addictive. In the most recent 12-month period, there were 109,600 drug overdose deaths in the United States, 70% of which were opioid-related. In 2023, 5.7 million people in the United States ages 12 and older have an opioid use disorder (OUD).

Although the numbers of opioid users needing treatment are high, most… no Get it. Some do not find it, others delay treatment, and others refuse it. In 2022, only about 25% of US adults with OUDs have received it medicine– Adjuvant therapy (MAT) such as methadone or buprenorphine.

Some people with OUD receive methadone at one of the 1,500 methadone maintenance treatment (MMT) clinics in the United States. Drs. Vincent Doll and Marie Neyswander were pioneers in MMT, conceptualizing OUD as a chronic metabolic disease in the mid-1960s. They argued that long-term therapy was a necessary medical treatment for OUD, just as insulin is for type 1 diabetes. Drawing on Dole’s background in endocrinology and metabolism, the researchers hypothesized that OUD causes permanent changes in brain and body chemistry. They called this “persistent jamming” of the opioid receptor system. They believed that this defect was the source of intense and persistent desire that led to Relapse Even after addicts get rid of drug toxins.

Rather than viewing addiction as an incurable character flaw, they argued that it should be treated as a medical condition. They found that methadone can stabilize “metabolic imbalance” by suppressing cravings and blocking the euphoric effects of other opioids, enabling individuals to function normally. In 1976, Dole and Neiswander addressed the common criticism that MMT was merely substituting one opioid drug for another. Critics failed to consider “the similar long-term use of other drugs such as insulin and digitalis in medical practice,” they wrote. By demonstrating that MMT can help formerly addicted people return to school, obtain jobs, and reintegrate into society, their research provided a powerful refutation of the moral view of addiction.

Methadone is a long-acting, oral opioid drug that does not provide the euphoric rush of other opioids, but is safe and effective as a treatment for OUD and prevents withdrawal symptoms. Some experts (myself included) believe that addiction doctors should be allowed to prescribe methadone, just as they prescribe buprenorphine, to be dispensed in local pharmacies.

After stopping treatment

Even when buprenorphine or methadone is used to treat OUD, it is important to consider what happens to people if treatment ends. Recently New England Journal of Medicine Research paper, A. Thomas McClellan, Ph.D., professor at the University of Pennsylvania, and Nora D. Volkow, MD, director of the National Research Institute drugproposed a patient-level “continuum of care” for OUD with three sequential lines Objectives: Protection → Forgiveness → Recovery.

McClellan and Volkow argue that recovery can occur while individuals remain on medication-assisted treatment with methadone or buprenorphine. They stress that abstinence is neither necessary nor sufficient to recover from OUD. They also argue that suddenly stopping drug treatment due to lack of progress or other reasons is dangerous.

The late Benji Brehm, MD, Herb Klepper, MD, and I have long agreed that patients need widespread access to methadone and buprenorphine. I have reviewed in detail Methadone maintenance successes Treatment since its beginning in the 1960s. Approximately 400,000 people in the United States are treated with methadone annually to treat OUD, yet buprenorphine is more widely prescribed.

After diagnosis or intervention, the first goal should be to focus on overdose protection. This means that once a diagnosis of OUD is made, drug treatment must be initiated, to prevent overdose as well as the risks of contracting HIV and other diseases from dirty needles to drug injections. Treatment with methadone or buprenorphine focuses on preventing overdose, preserving life, and keeping people in the program.

Ideally, a person suffering from OUD has remission from addiction or a significant and sustained reduction in OUD symptoms. This result may occur due to daily MAT dosing as well as the person’s involvement in psychosocial rehabilitation support.

It is important to understand that opioids cause changes in the brain no It can be reversed by abstinence. The main problem occurs when people carrying oud go on treatment. The risk of death from overdose is 3-4 times higher after detox than when continuing on buprenorphine or methadone; Keeping alone is strongly protective. In contrast, after stopping opioid treatment medications, the risk of relapse rebounds quickly — especially in the first month, when a previously low dose of the drug can kill users because their tolerance to the drug is now low.

Within this regimen, remission is possible, and the individual may have a sustained and stable recovery after 12 months. With opioid use disorders, as opposed to addiction to cocaine, methamphetamine, cannabis, or even AlcoholThere must be a clear focus on initial treatment, which, above all, prevents deaths from overdose.

Why do so many people with ouds say no to MAT providers?

There are several factors that limit access to OUD medications. According to a study by the Centers for Disease Control and Prevention, approximately 43% of adults who needed OUD treatment did not agree that they needed it. I find that keeping MMT is life-saving, but they may view it as ongoing chemical slavery. They may also choose buprenorphine because it is easier to stop taking than methadone. Doctor and program preferences can also play a role.

The recent McLellan/Volkow NEJM article serves as a reminder that Doll and Neiswander were right to suggest that we did not have (and still do not have) a way to reverse the effects of opioids on the brain. We finally need to reject time-limited OUD detox as a primary treatment goal and not discontinue medication with incomplete progress. Patients should be referred to high-intensity residential services if necessary.

Brian Furlin, MD, of Yale University, has observed in the emergency room that many patients are saved with Narcan, leave, and refuse other treatments. Doctors try to use this teaching moment to get the person, family, and other loved ones involved in the intervention to start buprenorphine right away. It is not clear what to do about treatment refusal and early dropout, other than building rapport and trust, and working together to reduce overdoses among people who are not ready for treatment.

Conclusions

In the 1960s, Doll and Neiswander hypothesized that OUD is a chronic “metabolic disease” that involves permanent physiological changes. They concluded that abstinence was unrealistic because the metabolic deficiency would persist. Therefore, they have advocated methadone maintenance therapy as a long-term, often lifelong, treatment to stabilize this condition. There is no arbitrary time limit, and treatment should continue as long as it is beneficial for the patient and recovery does not require tapering of opioids. We need to face reality, confront the conditions that people addicted to opioids live in, and help them survive, cope, and recover.

We don’t have treatments like penicillin for strep throat. Relapse is common, residual problems often persist, and treatment-resistant opioid use disorder has been reported.